IN2014MN02598A - - Google Patents

Info

Publication number
IN2014MN02598A
IN2014MN02598A IN2598MUN2014A IN2014MN02598A IN 2014MN02598 A IN2014MN02598 A IN 2014MN02598A IN 2598MUN2014 A IN2598MUN2014 A IN 2598MUN2014A IN 2014MN02598 A IN2014MN02598 A IN 2014MN02598A
Authority
IN
India
Prior art keywords
compounds
disclosed
formula
methods
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Kyla Bjornson
Eda Canales
Jeromy J Cottell
Kapil Kumar Karki
Ashley Anne Katana
Darryl Kato
Tetsuya Kobayashi
John O Link
Ruben Martinez
Barton W Phillips
Hyung Jung Pyun
Michael Sangi
Adam James Schrier
Dustin Siegel
James G Taylor
Chinh Viet Tran
Martin Teresa Alejandra Trejo
Randall W Vivian
Zheng Yu Yang
Jeff Zablocki
Sheila Zipfel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of IN2014MN02598A publication Critical patent/IN2014MN02598A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IN2598MUN2014 2012-07-03 2013-07-02 IN2014MN02598A (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261667806P 2012-07-03 2012-07-03
US201361798524P 2013-03-15 2013-03-15
PCT/US2013/049119 WO2014008285A1 (en) 2012-07-03 2013-07-02 Inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
IN2014MN02598A true IN2014MN02598A (ro) 2015-07-24

Family

ID=48803614

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2598MUN2014 IN2014MN02598A (ro) 2012-07-03 2013-07-02

Country Status (41)

Country Link
US (7) US20150175655A1 (ro)
EP (4) EP2870160B1 (ro)
JP (4) JP6025977B2 (ro)
KR (3) KR101610575B1 (ro)
CN (2) CN106117309B (ro)
AP (1) AP3903A (ro)
AR (1) AR091661A1 (ro)
AU (6) AU2013286729B2 (ro)
BR (2) BR112014033080B1 (ro)
CA (1) CA2877005C (ro)
CL (1) CL2014003634A1 (ro)
CO (1) CO7160104A2 (ro)
CR (1) CR20150045A (ro)
CY (2) CY1118379T1 (ro)
DK (2) DK3159345T3 (ro)
EA (2) EA027390B1 (ro)
EC (1) ECSP15002066A (ro)
ES (3) ES2716138T3 (ro)
HK (2) HK1209416A1 (ro)
HR (2) HRP20161379T1 (ro)
HU (2) HUE032404T2 (ro)
IL (4) IL236500B (ro)
IN (1) IN2014MN02598A (ro)
LT (2) LT3159345T (ro)
MD (2) MD20180040A2 (ro)
ME (2) ME02547B (ro)
MX (2) MX360597B (ro)
MY (1) MY173342A (ro)
NZ (2) NZ739248A (ro)
PE (1) PE20150204A1 (ro)
PH (3) PH12014502862B1 (ro)
PL (2) PL2870160T3 (ro)
PT (2) PT3159345T (ro)
RS (2) RS58409B1 (ro)
SG (3) SG11201408739VA (ro)
SI (2) SI2870160T1 (ro)
SM (1) SMT201600470B (ro)
TW (1) TWI602822B (ro)
UA (1) UA119315C2 (ro)
UY (1) UY34888A (ro)
WO (1) WO2014008285A1 (ro)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之***酮化合物
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
MA37992B1 (fr) 2012-10-19 2018-09-28 Bristol Myers Squibb Co Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c.
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
ES2735355T3 (es) * 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
ES2708993T3 (es) 2013-12-23 2019-04-12 Gilead Sciences Inc Formas cristalinas de un tripéptido macrocíclico inhibidor de NS3 del VHC
JP6425727B2 (ja) * 2013-12-23 2018-11-21 ギリアード サイエンシーズ， インコーポレイテッド 大環状ｈｃｖ ｎｓ３阻害トリペプチド
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JP6643735B2 (ja) * 2015-02-16 2020-02-12 セントラル硝子株式会社 含フッ素α−ケトカルボン酸エステル類の実用的な製造方法
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
JP6770098B2 (ja) 2016-05-27 2020-10-14 ギリアード サイエンシーズ， インコーポレイテッド Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
JOP20190052A1 (ar) 2016-09-22 2019-03-21 Astrazeneca Ab 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز
CN110461812A (zh) * 2017-02-01 2019-11-15 艾伯维公司 用于制备(±)-2-(二氟甲基)-1-(烷氧基羰基)-环丙烷甲酸和(±)-2-(乙烯基)-1-(烷氧基羰基)-环丙烷甲酸的酶促方法
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN111018795B (zh) * 2019-12-25 2023-03-28 上海彩迩文生化科技有限公司 一种碱性条件下合成喹喔啉-3-酮的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031905A1 (es) 2000-12-12 2003-10-08 Schering Corp Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c
CA2465247C (en) 2001-10-26 2010-05-18 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
WO2004043339A2 (en) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
ATE503764T1 (de) 2002-05-20 2011-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
PT1615613E (pt) 2003-04-18 2010-02-09 Enanta Pharm Inc Inibidores da serina protease da hepatite c macrocíclicos de quinoxalinilo
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
MY143076A (en) 2003-05-21 2011-02-28 Boehringer Ingelheim Int Hepatitis c inhibitors compounds
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2316839B1 (en) 2004-07-16 2014-03-12 Gilead Sciences, Inc. Antiviral heterocyclic compounds having phosphonate groups
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
CN101263156A (zh) 2005-07-25 2008-09-10 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
EP1913016B1 (en) * 2005-08-01 2013-01-16 Merck Sharp & Dohme Corp. Macrocyclic peptides as hcv ns3 protease inhibitors
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽
ATE493409T1 (de) 2005-10-11 2011-01-15 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
WO2008051475A2 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
ES2444575T3 (es) 2006-10-27 2014-02-25 Merck Sharp & Dohme Corp. Inhibidores de la proteasa NS3 del VHC
CA2667031C (en) 2006-10-27 2013-01-22 Merck & Co., Inc. Hcv ns3 protease inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
WO2008137779A2 (en) 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CL2008001381A1 (es) 2007-05-10 2008-11-03 Intermune Inc Y Array Biopharma Inc Compuestos derivados de tripeptidos que contienen heterociclos nitrogenados; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una infeccion de hepatitis c o vih.
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
KR20100038417A (ko) 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
JP5465666B2 (ja) 2007-06-29 2014-04-09 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
JP2010540549A (ja) 2007-09-24 2010-12-24 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製阻害剤としての尿素含有ペプチド
WO2009055467A2 (en) 2007-10-24 2009-04-30 Virobay, Inc. Compounds that inhibit protease cathepsin s and hcv replication
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
WO2009070689A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
US8962551B2 (en) 2007-12-05 2015-02-24 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
WO2009082697A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CN102036966A (zh) 2008-01-24 2011-04-27 益安药业 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽
ES2437147T3 (es) 2008-02-04 2014-01-09 Idenix Pharmaceuticals, Inc. Inhibidores de serina proteasa macrocíclicos
AU2009217551B2 (en) 2008-02-25 2014-07-31 Msd Italia S.R.L. Therapeutic compounds
US8431733B2 (en) 2008-03-12 2013-04-30 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2720850A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
CA2731177C (en) 2008-07-22 2013-10-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
CN102112442B (zh) 2008-08-07 2014-12-10 弗·哈夫曼-拉罗切有限公司 制备大环的方法
EP2334680A2 (en) 2008-08-20 2011-06-22 Sequoia Pharmaceuticals, Inc. Hcv protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
MY153093A (en) 2008-09-16 2014-12-31 Boehringer Ingelheim Int Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2740728A1 (en) 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
EP2364159A4 (en) 2008-10-23 2012-06-13 Concert Pharmaceuticals Inc DETERIORIC MACROCYCLIC INHIBITORS OF NS3 VIRAL PROTEASE
AU2009316472B2 (en) 2008-11-20 2015-07-09 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus
SI2358355T1 (sl) 2008-11-21 2014-02-28 Boehringer Ingelheim Gmbh Farmacevtski sestavek potentnega inhibitorja HCV za oralno dajanje
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20100152103A1 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR074670A1 (es) 2008-12-19 2011-02-02 Gilead Sciences Inc Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c
SI2382198T1 (sl) 2008-12-23 2013-11-29 Janssen Pharmaceuticals, Inc. Postopek in vmesne spojine za pripravo makrocikličnega inhibitorja HCV proteaze
WO2010132163A1 (en) 2009-05-13 2010-11-18 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
EP2432318A4 (en) 2009-05-22 2012-11-21 Sequoia Pharmaceuticals Inc NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
DK2459554T3 (da) 2009-07-31 2014-01-06 Cadila Healthcare Ltd Substituerede benzamidderivater som glucokinase (GK)-aktivatorer
CN102470158A (zh) 2009-08-27 2012-05-23 默沙东公司 制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法
CN105001302A (zh) 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
WO2011041551A1 (en) 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
US9193740B2 (en) 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
NZ602288A (en) 2010-03-10 2014-02-28 Abbvie Bahamas Ltd Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
JP2013528217A (ja) 2010-06-07 2013-07-08 アッヴィ・インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害薬
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2012037259A1 (en) 2010-09-15 2012-03-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2618665A4 (en) 2010-09-21 2014-08-20 Merck Sharp & Dohme HCV NS3 PROTEASE INHIBITORS
ES2560003T3 (es) 2010-09-21 2016-02-17 Enanta Pharmaceuticals, Inc. Inhibidores de la serina proteasa de VHC derivados de prolina macrocíclica
WO2012040242A1 (en) 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
WO2012054874A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.
KR20130143084A (ko) 2010-12-14 2013-12-30 머크 샤프 앤드 돔 코포레이션 마크로락탐의 제조 방법 및 중간체
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6110846B2 (ja) 2011-05-27 2017-04-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2012269643A1 (en) 2011-06-16 2014-02-06 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
EP2744336B1 (en) 2011-08-19 2017-07-05 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
BR112014010545A2 (pt) 2011-10-31 2017-05-02 Merk Sharp & Dohme Corp composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
WO2013106506A1 (en) 2012-01-12 2013-07-18 Boehringer Ingelheim International Gmbh Stabilized pharmaceutical formulations of a potent hcv inhibitor
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C

Also Published As

Publication number Publication date
EP2870160A1 (en) 2015-05-13
US10335409B2 (en) 2019-07-02
CA2877005A1 (en) 2014-01-09
MX2014015846A (es) 2015-08-14
KR20160040743A (ko) 2016-04-14
AU2013286729A1 (en) 2015-01-22
AU2013286729B2 (en) 2015-11-12
RS55494B1 (sr) 2017-04-28
EA201790661A2 (ru) 2017-08-31
AU2017203984A1 (en) 2017-07-06
US20190365748A1 (en) 2019-12-05
PH12014502862A1 (en) 2015-02-23
ES2605383T3 (es) 2017-03-14
CN106117309B (zh) 2019-08-30
EA201790661A3 (ru) 2017-10-31
CN106117309A (zh) 2016-11-16
KR101610575B1 (ko) 2016-04-07
US9655944B2 (en) 2017-05-23
IL252446A0 (en) 2017-07-31
LT3159345T (lt) 2019-03-12
ME03362B (me) 2019-10-20
WO2014008285A1 (en) 2014-01-09
EA201492214A1 (ru) 2015-10-30
PL2870160T3 (pl) 2017-05-31
ECSP15002066A (es) 2015-11-30
UA119315C2 (uk) 2019-06-10
BR112014033080A2 (pt) 2017-06-27
PT2870160T (pt) 2016-12-12
EP3492464A1 (en) 2019-06-05
PH12016502040A1 (en) 2019-02-27
MX360597B (es) 2018-11-09
US20160130300A1 (en) 2016-05-12
KR20190124346A (ko) 2019-11-04
CR20150045A (es) 2015-05-13
EA033961B1 (ru) 2019-12-13
NZ739248A (en) 2019-05-31
TW201414740A (zh) 2014-04-16
JP2020143107A (ja) 2020-09-10
JP2015523365A (ja) 2015-08-13
TWI602822B (zh) 2017-10-21
SMT201600470B (it) 2017-03-08
EP3492464B1 (en) 2020-08-19
CO7160104A2 (es) 2015-01-15
UY34888A (es) 2014-01-31
DK2870160T3 (en) 2017-01-23
IL236500A0 (en) 2015-02-26
PE20150204A1 (es) 2015-02-12
SG11201408739VA (en) 2015-01-29
IL261581A (en) 2018-10-31
IL269662A (en) 2019-11-28
MX2018013668A (es) 2019-01-28
RS58409B1 (sr) 2019-04-30
US20170290827A1 (en) 2017-10-12
KR102040023B1 (ko) 2019-11-05
US20140017198A1 (en) 2014-01-16
ES2716138T3 (es) 2019-06-10
CA2877005C (en) 2016-12-13
CY1121418T1 (el) 2020-05-29
AU2016200201A1 (en) 2016-02-04
US9296782B2 (en) 2016-03-29
SG10201702950TA (en) 2017-06-29
LT2870160T (lt) 2016-12-12
EP3159345B1 (en) 2019-01-09
HUE042345T2 (hu) 2019-06-28
AU2019222909B2 (en) 2021-03-25
US10603318B2 (en) 2020-03-31
KR20150034698A (ko) 2015-04-03
NZ703064A (en) 2016-12-23
HK1209416A1 (en) 2016-04-01
ES2827300T3 (es) 2021-05-20
HUE032404T2 (en) 2017-09-28
CY1118379T1 (el) 2017-06-28
JP2016041743A (ja) 2016-03-31
MD20180040A2 (ro) 2018-11-30
AU2016200670A1 (en) 2016-02-25
SG10201912269YA (en) 2020-02-27
US20160361375A1 (en) 2016-12-15
ME02547B (me) 2017-02-20
MD20140136A2 (ro) 2015-05-31
EP2870160B1 (en) 2016-09-28
EP3825312A1 (en) 2021-05-26
AP2014008166A0 (en) 2014-12-31
AU2019222909A1 (en) 2019-09-19
AU2017203984B2 (en) 2019-06-06
SI2870160T1 (sl) 2016-11-30
PL3159345T3 (pl) 2019-09-30
AR091661A1 (es) 2015-02-18
PH12020550552A1 (en) 2021-07-26
AU2021204238A1 (en) 2021-07-22
DK3159345T3 (en) 2019-03-25
MY173342A (en) 2020-01-17
US20150175655A1 (en) 2015-06-25
IL261581B (en) 2019-10-31
EA027390B1 (ru) 2017-07-31
HRP20161379T1 (hr) 2016-12-02
HRP20190578T1 (hr) 2019-05-17
JP6025977B2 (ja) 2016-11-16
CN104540832B (zh) 2016-08-24
US20190008858A1 (en) 2019-01-10
JP2018154651A (ja) 2018-10-04
IL236500B (en) 2018-02-28
HK1210151A1 (en) 2016-04-15
MD4602B1 (ro) 2018-11-30
CN104540832A (zh) 2015-04-22
EP3159345A1 (en) 2017-04-26
CL2014003634A1 (es) 2015-11-06
PT3159345T (pt) 2019-04-15
SI3159345T1 (sl) 2019-03-29
PH12014502862B1 (en) 2015-02-23
AP3903A (en) 2016-11-17
BR122021012378B1 (pt) 2022-05-10
BR112014033080B1 (pt) 2022-03-29

Similar Documents

Publication Publication Date Title
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
IN2015DN01119A (ro)
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
MX2016006336A (es) Compuestos pirazolopirimidina.
IN2014CN04530A (ro)
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2014MN02652A (ro)
IN2014MN02657A (ro)
NZ703162A (en) Heterocyclic modulators of lipid synthesis
MD20160136A2 (ro) Compuşi dihidroizochinolinonici substituiţi
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
GB201209587D0 (en) Therapeutic compounds
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
GEP201706675B (en) Imidazo-triazine derivatives as pde10 inhibitors
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors